(MENAFN- America News Hour) Research Nester published a report titled “Lassa Fever Treatment Market : Global Demand Analysis & Opportunity Outlook 2030” which delivers detailed overview of theglobalLassa fever treatment market in terms of market segmentation by symptoms, treatment, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The globalLassa fever treatment market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2030. The market is segmented on the basis of treatment into medication, supportive care, and others, out of which, the medication segment is projected to hold the largest market share over the forecast period on account easy availability of medicines, such as, ribavirin, along with faster relief in symptoms. Ribavirin is the most commonly used drug to treat Lassa fever.
The globalLassa fever treatment market is foreseen to grow on the back of increasing prevalence of the disease, severe symptoms, and chronic nature of the disease. According to the data by the World Health Organization (WHO), Lassa fever causes deafness in 25% of the cases, while vital organs are affected in 1 out of 5 cases. Lassa fever majorly affects the brain, and can even result in coma, f the infection is severe. The causes of the disease include consumption of food infected with rodent urine or excreta. Lack of proper sanitation facilities and awareness regarding cleanliness is estimated to boost the market growth. Moreover, growing health awareness amongst the people is anticipated to boost the market growth.
Download Sample of This Strategic Report@
On the basis of geographical analysis, the global Lassa fever treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa region is projected to witness noteworthy growth over the forecast period owing to the increasing incidences of Lassa fever in the region. Moreover, absence of proper sanitation services, such as, toilets, in the region is further expected to boost the market growth. According to the statistics by the WHO, around 2 billion people do not have basic sanitation facilities, such as, toilets, especially in middle and low-income economies.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players' competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Lack of Proper Hygiene and Sanitation to Boost the Market Growth
Lack of cleanliness is the biggest cause of Lassa fever, as it promotes rodent infestation. Middle and low-income countries lack proper sanitation services, owing to the large rural population, and low disposal income. Such factors are estimated to boost the market growth.
Download/Request Sample Copy of Strategic Report:
However, lack of health awareness amongst people in the low-income countries is expected to operate as key restraint to the growth of the global Lassa fever treatment market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global Lassa fever treatment market which includes company profiling of Mylan N.V., Pfizer, Inc., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd, Abbott Laboratories, and Cipla Limited. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Lassa fever treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
More Information@
About Research Nester
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
AJ Daniel
Email:
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919
Research Nester
Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.
MENAFN19102021004545010068ID1102997973
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.